Pharmaceutical registration in Africa is still done country by country. To sell a medicine in Nigeria, Kenya or South Africa, you need a marketing authorisation from that country's national regulator, usually applied for through a locally established company. The African Medicines Agency (AMA) became operational in Kigali in October 2025, but as of November 2026 it does not issue continental marketing authorisations: it coordinates regulators and provides scientific assessments that national authorities can rely on. The practical shortcuts today are reliance routes, such as the WHO Collaborative Registration Procedure, and regional joint reviews like ZaZiBoNa in southern Africa and the East African Community's joint assessments.
This guide explains each route, what the AMA does and does not do yet, and where local manufacturing fits.
The African Medicines Agency: status as of 17 November 2026
The AMA is the African Union's continental medicines regulator. Its precise status:
| Fact |
Detail |
Source |
| Treaty adopted |
11 February 2019, AU Assembly, Addis Ababa |
AMA |
| Treaty in force |
5 November 2021, after the 15th ratification |
AMA |
| Ratifications |
33 of 55 AU member states (AMA website, checked 17 November 2026) |
AMA |
| Director General |
Dr Delese Mimi Darko (Ghana), the inaugural Director General |
AMA |
| Operational since |
October 2025, when the Director General took office at the Kigali headquarters |
AMA |
| Technical committees |
Seven inaugurated during AMA Week, 25–30 October 2026, covering evaluation of medicines, vaccines and biologicals; clinical trials; market intelligence and control; quality-control laboratories; vigilance; inspections; and medical devices and diagnostics |
allAfrica, 28 October 2026 |
| New platforms |
A Capacity Strengthening Hub and a Regulatory Innovation and Manufacturing Readiness Hub, launched during AMA Week |
Pan African Visions, November 2026 |
What the AMA does not do yet
- No continental marketing authorisation. National authorities keep responsibility for their own regulatory decisions (allAfrica). In a July 2026 interview, Dr Darko described continental approval of certain products as future work, and said that what the AMA gives is a scientific opinion or recommendation that national regulators can use (Health Policy Watch, 27 July 2026).
- No published product evaluations. We found no public record of a completed AMA product evaluation as of mid-November 2026. The technical committees that will carry out evaluations were inaugurated only in late October 2026.
- Not every product. The AMA's treaty scope covers "selected medical products", with a focus on complex products, vaccines and products of public-health importance such as malaria and tuberculosis tools. Dr Darko said it would not necessarily get involved with products like antibiotics or paracetamol (Health Policy Watch).
- Not every country. Only states that have ratified the treaty are AMA State Parties. Check whether your target market is one of the 33 before building a plan around AMA reliance.
What this means for a manufacturer in 2026: plan on national registration. Treat the AMA as a route that may shorten some reviews for priority products in coming years, not as a filing option today.
Route 1: National registration
Every country runs its own process, but the shape is similar:
- Appoint a local applicant. Most regulators require a locally established company to hold or apply for the registration. In Nigeria, a foreign manufacturer must be represented by a registered Nigerian pharmaceutical company, or set up its own local entity, and supply a power of attorney naming the products (Mondaq summary of NAFDAC requirements). In South Africa, SAHPRA's guidance requires co-applicants to be legal entities domiciled in South Africa (SAHPRA co-applicancy guideline).
- Prepare the dossier. Expect the Common Technical Document (CTD) structure with a country-specific Module 1. SAHPRA, for example, publishes its own eCTD specification and Module 1 guidance.
- Supply the supporting certificates. NAFDAC's list, for example, includes a Certificate of Pharmaceutical Product (CPP) in WHO format issued by the regulator in the country of manufacture, a certificate of free sale, certificates of analysis and a notarised power of attorney (Mondaq).
- Pass GMP inspection or desk review. Regulators may inspect your plant or rely on another authority's inspection.
- Pay fees and wait. Fees and timelines are set by each regulator and change often. Check the current schedule on the regulator's site before you budget.
Regulator maturity matters
The WHO benchmarks national regulators with its Global Benchmarking Tool. Maturity level 3 (ML3) means a "stable, well-functioning and integrated regulatory system". As of August 2026, the African regulators at ML3 were (WHO list, August 2026):
| Country |
Regulator |
Scope at ML3 |
| Egypt |
Egyptian Drug Authority |
Medicines; vaccines (producing) |
| Ethiopia |
Ethiopian Food and Drug Authority |
Medicines; vaccines (non-producing) |
| Ghana |
Food and Drugs Authority |
Medicines; vaccines (non-producing) |
| Mozambique |
ANARME |
Medicines; vaccines (non-producing) |
| Nigeria |
NAFDAC |
Medicines; vaccines (non-producing) |
| Rwanda |
Rwanda FDA |
Medicines; vaccines (non-producing) |
| Senegal |
Agence sénégalaise de Réglementation Pharmaceutique |
Medicines; vaccines (non-producing) |
| South Africa |
SAHPRA |
Vaccines (producing) |
| Tanzania |
TMDA |
Medicines; vaccines (non-producing) |
| Zimbabwe |
MCAZ |
Medicines; vaccines (non-producing) |
Dr Darko has said the AMA's initial backbone will be the ML3 agencies (Health Policy Watch). For a manufacturer, a registration with one of these regulators is also a strong reference when applying elsewhere. Note that South Africa's ML3 listing covers vaccine regulation only.
Route 2: Reliance through WHO prequalification
If your product is WHO-prequalified, the WHO Collaborative Registration Procedure (CRP) lets participating national regulators use WHO's assessment and inspection reports. A regulator that agrees to apply the procedure to your product commits to a decision within 90 days of receiving access to those reports.
The CRP suits products bought through international procurement (HIV, malaria, tuberculosis, reproductive health, vaccines). It does not remove national fees or the local applicant requirement, and real-world timelines can run longer than the 90-day target, so plan buffer time.
Route 3: Regional joint assessment
Regional economic communities run joint reviews under the African Medicines Regulatory Harmonisation (AMRH) programme. You still receive separate national authorisations, but the scientific review is shared.
ZaZiBoNa started in 2013 with Zambia, Zimbabwe, Botswana and Namibia (hence the name) and now involves all SADC member states as active or non-active participants. Applicants submit one dossier in the SADC common format; the participating regulators assess it jointly, and each issues its own decision (Sithole et al., Frontiers in Medicine, 2022).
The EAC runs a joint assessment procedure for its member states. During AMA Week, the median review time under EAC joint assessments was reported to have fallen from 553 days in 2015 to 259 days in 2023 (allAfrica, 28 October 2026).
Choosing between routes
| Route |
Best for |
What you still need |
| National only |
One or two priority markets |
Local applicant, full dossier per country |
| WHO CRP |
Prequalified products in donor-funded markets |
Prequalification first; national fees |
| ZaZiBoNa / EAC joint assessment |
Several markets in one region |
One shared dossier, then national decisions and fees |
| AMA (future) |
Priority and complex products |
Not yet a filing route as of November 2026 |
Commercial set-up: who holds the registration?
The registration holder controls the product in that market. Before you sign with a distributor, decide:
- Who holds the marketing authorisation. If the distributor holds it, changing distributors can mean transferring or re-registering. Many manufacturers keep the registration in their own local subsidiary or a neutral regulatory agent and license the distributor separately.
- Who handles pharmacovigilance. Agree in writing who collects adverse-event reports and files them with each regulator.
- How the distributor is vetted. See our guide to finding and checking a distributor in Africa, and compare entry structures in export, JV, subsidiary or franchise.
Local manufacturing
African governments and funders want more medicines and vaccines made on the continent, and regulation is part of that push.
- Regulatory support. The AMA's new Regulatory Innovation and Manufacturing Readiness Hub is intended to let manufacturers engage regulators early and understand evidence expectations (Pan African Visions).
- Vaccine finance. Gavi's African Vaccine Manufacturing Accelerator can make up to US$1.2 billion available over ten years from its June 2024 launch, paid per dose to manufacturers producing vaccines in Africa.
- Regulator capacity. On the WHO list, Egypt and South Africa are the African regulators benchmarked at ML3 for vaccine-producing countries, which matters if you plan to make vaccines rather than import them.
For a foreign manufacturer, local production can mean contract manufacturing with an African plant, technology transfer, or a joint venture. Each still needs a registration in every market where the product is sold. A product made in Kenya is not automatically registered in Tanzania.
Trade rules for medicines
Within Africa, the AfCFTA can lower tariffs on medicines as countries phase in their schedules. Check your product's HS code and the relevant country pair in the AfCFTA e-Tariff Book, and see our AfCFTA overview. Tariff relief does not replace registration: a medicine must still be authorised in the importing country.
A practical sequence for 2026–27
- Pick two or three priority markets, ideally including one ML3 regulator.
- Check whether the product is, or could be, WHO-prequalified; if so, use the CRP where available.
- For a regional roll-out, file through ZaZiBoNa or the EAC joint procedure.
- Set up a local applicant you control, and separate it from your distribution agreement.
- Watch the AMA: if your product is in a priority category, track when its evaluation committee starts accepting work and which State Parties will rely on its opinions.
Bottom line
In November 2026, selling medicines into Africa still means national registration, made faster by reliance and regional joint reviews. The African Medicines Agency is real and operational, with a Director General, headquarters, 33 State Parties and newly formed technical committees, but it is not yet a place to file for a continental licence. Build your plan on national and regional routes, and treat the AMA as an emerging option for priority products.
To see which markets we cover, visit /markets.
AfroSynergy connects international buyers with African exporters. Listings open on 15 January 2027. To source a product or find a counterparty now, send us an enquiry.